Faecal proteomics links neutrophil degranulation with mortality in patients with alcohol-associated hepatitis.

in Gut by Henriette Kreimeyer, Carlos G Gonzalez, Marcos F Fondevila, Cynthia L Hsu, Phillipp Hartmann, Xinlian Zhang, Peter Stärkel, Francisco Bosques-Padilla, Elizabeth C Verna, Juan G Abraldes, Robert S Brown, Victor Vargas, Jose Altamirano, Juan Caballería, Debbie L Shawcross, Alexandre Louvet, Michael R Lucey, Philippe Mathurin, Guadalupe Garcia-Tsao, Ramón Bataller, AlcHepNet Investigators, David J Gonzalez, Bernd Schnabl

TLDR

  • The study looked at proteins in the poop of people with alcohol-associated hepatitis (AH) and compared them to the proteins in the poop of people who didn't drink alcohol and people who drank alcohol but didn't have AH. The study found that the proteins in the poop of people with AH were different from the proteins in the poop of the other groups. The study also found that one of these proteins, myeloperoxidase, could predict how long people with AH would live. The study suggests that the proteins in the poop of people with AH could be used to diagnose and predict the outcome of the disease.

Abstract

Patients with alcohol-associated hepatitis (AH) have a high mortality. Alcohol exacerbates liver damage by inducing gut dysbiosis, bacterial translocation and inflammation, which is characterised by increased numbers of circulating and hepatic neutrophils. In this study, we performed tandem mass tag (TMT) proteomics to analyse proteins in the faeces of controls (n=19), patients with alcohol-use disorder (AUD; n=20) and AH (n=80) from a multicentre cohort (InTeam). To identify protein groups that are disproportionately represented, we conducted over-representation analysis using Reactome pathway analysis and Gene Ontology to determine the proteins with the most significant impact. A faecal biomarker and its prognostic effect were validated by ELISA in faecal samples from patients with AH (n=70), who were recruited in a second and independent multicentre cohort (AlcHepNet). Faecal proteomic profiles were overall significantly different between controls, patients with AUD and AH (principal component analysis p=0.001, dissimilarity index calculated by the method of Bray-Curtis). Proteins that showed notable differences across all three groups and displayed a progressive increase in accordance with the severity of alcohol-associated liver disease were predominantly those located in neutrophil granules. Over-representation and Reactome analyses confirmed that differentially regulated proteins are part of granules in neutrophils and the neutrophil degranulation pathway. Myeloperoxidase (MPO), the marker protein of neutrophil granules, correlates with disease severity and predicts 60-day mortality. Using an independent validation cohort, we confirmed that faecal MPO levels can predict short-term survival at 60 days. We found an increased abundance of faecal proteins linked to neutrophil degranulation in patients with AH, which is predictive of short-term survival and could serve as a prognostic non-invasive marker.

Overview

  • The study aimed to analyze proteins in the faeces of controls, patients with alcohol-use disorder (AUD), and alcohol-associated hepatitis (AH) from a multicentre cohort (InTeam) using tandem mass tag (TMT) proteomics to identify protein groups that are disproportionately represented. The study conducted over-representation analysis using Reactome pathway analysis and Gene Ontology to determine the proteins with the most significant impact. The primary objective of the study was to identify a faecal biomarker and its prognostic effect in patients with AH, which was validated by ELISA in faecal samples from patients with AH recruited in a second and independent multicentre cohort (AlcHepNet).
  • Methodology and Subject Demographics: The study used TMT proteomics to analyze proteins in the faeces of controls, patients with AUD, and AH from a multicentre cohort (InTeam). The study included 19 controls, 20 patients with AUD, and 80 patients with AH. The study used over-representation analysis using Reactome pathway analysis and Gene Ontology to determine the proteins with the most significant impact. The study validated the findings using ELISA in faecal samples from patients with AH recruited in a second and independent multicentre cohort (AlcHepNet).
  • Primary Objective: The primary objective of the study was to identify a faecal biomarker and its prognostic effect in patients with AH, which was validated by ELISA in faecal samples from patients with AH recruited in a second and independent multicentre cohort (AlcHepNet).

Comparative Analysis & Findings

  • The study found that faecal proteomic profiles were overall significantly different between controls, patients with AUD, and AH. Proteins that showed notable differences across all three groups and displayed a progressive increase in accordance with the severity of alcohol-associated liver disease were predominantly those located in neutrophil granules. Over-representation and Reactome analyses confirmed that differentially regulated proteins are part of granules in neutrophils and the neutrophil degranulation pathway. Myeloperoxidase (MPO), the marker protein of neutrophil granules, correlates with disease severity and predicts 60-day mortality. Using an independent validation cohort, the study confirmed that faecal MPO levels can predict short-term survival at 60 days. The study found an increased abundance of faecal proteins linked to neutrophil degranulation in patients with AH, which is predictive of short-term survival and could serve as a prognostic non-invasive marker.

Implications and Future Directions

  • The study's findings suggest that faecal proteomic profiles can be used to identify biomarkers for the diagnosis and prognosis of AH. The study's findings also suggest that neutrophil degranulation plays a crucial role in the development of AH. The study's findings could be used to develop non-invasive diagnostic and prognostic tools for AH. Future research could focus on validating the use of faecal proteomic profiles as a diagnostic and prognostic tool for AH in larger and more diverse populations. Future research could also focus on identifying other proteins that are differentially regulated in patients with AH and their role in the development and progression of the disease.